Rhumbline Advisers 89bio, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in 89bio, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 128,944 shares of ETNB stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
128,944
Previous 101,610
26.9%
Holding current value
$1.29 Million
Previous $1.18 Million
12.69%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ETNB
# of Institutions
157Shares Held
107MCall Options Held
65KPut Options Held
1.2M-
Ra Capital Management, L.P. Boston, MA14.2MShares$141 Million1.71% of portfolio
-
Janus Henderson Group PLC London, X013.3MShares$132 Million0.06% of portfolio
-
Suvretta Capital Management, LLC New York, NY8.03MShares$80.1 Million2.69% of portfolio
-
Bvf Inc San Francisco, CA7.57MShares$75.5 Million1.85% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$73.6 Million0.99% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $463M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...